oru.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery
Institute of Pathology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Biotechnology for Health and Well-being, VTT Technical Research Centre of Finland, Espoo and Turku, Finland.
Biotechnology for Health and Well-being, VTT Technical Research Centre of Finland, Espoo and Turku, Finland.
Department of Biochemistry, University of Cambridge, Cambridge, UK.
Show others and affiliations
2012 (English)In: Genome Medicine, ISSN 1756-994X, E-ISSN 1756-994X, Vol. 4, no 4, article id 37Article, review/survey (Refereed) Published
Abstract [en]

Breast cancer is the most common cancer in women worldwide, and the development of new technologies for better understanding of the molecular changes involved in breast cancer progression is essential. Metabolic changes precede overt phenotypic changes, because cellular regulation ultimately affects the use of small-molecule substrates for cell division, growth or environmental changes such as hypoxia. Differences in metabolism between normal cells and cancer cells have been identified. Because small alterations in enzyme concentrations or activities can cause large changes in overall metabolite levels, the metabolome can be regarded as the amplified output of a biological system. The metabolome coverage in human breast cancer tissues can be maximized by combining different technologies for metabolic profiling. Researchers are investigating alterations in the steady state concentrations of metabolites that reflect amplified changes in genetic control of metabolism. Metabolomic results can be used to classify breast cancer on the basis of tumor biology, to identify new prognostic and predictive markers and to discover new targets for future therapeutic interventions. Here, we examine recent results, including those from the European FP7 project METAcancer consortium, that show that integrated metabolomic analyses can provide information on the stage, subtype and grade of breast tumors and give mechanistic insights. We predict an intensified use of metabolomic screens in clinical and preclinical studies focusing on the onset and progression of tumor development.

Place, publisher, year, edition, pages
London, United Kingdom: BioMed Central, 2012. Vol. 4, no 4, article id 37
Keywords [en]
Breast cancer, metabolomics, lipidomics, biomarker analysis
National Category
Medical and Health Sciences Cancer and Oncology
Identifiers
URN: urn:nbn:se:oru:diva-63729DOI: 10.1186/gm336ISI: 000314569200008PubMedID: 22546809Scopus ID: 2-s2.0-84860491505OAI: oai:DiVA.org:oru-63729DiVA, id: diva2:1169316
Funder
EU, European Research CouncilAvailable from: 2017-12-23 Created: 2017-12-23 Last updated: 2018-05-15Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopusFulltext

Authority records BETA

Oresic, Matej

Search in DiVA

By author/editor
Oresic, Matej
In the same journal
Genome Medicine
Medical and Health SciencesCancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 32 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf